Traphaco is the most prestigious oriental medicine company in Vietnam's pharmaceutical industry for the second time in a row

On January 14^th, 2022 at Vietnam National Convention Center, Hanoi City, Traphaco is honored for the second time in a row as the most prestigious oriental medicine company in Vietnam's pharmaceutical industry. The ceremony was organized by Vietnam Report Joint Stock Company (Vietnam Report) in collaboration with VietnamNet Newspaper - Ministry of Information and Communications.

Ms. Dao Thuy Ha - COO of Sales & Marketing on behalf of Traphaco JSC received the certificate

The list is built on scientific and objective principles. Companies are evaluated and ranked based on 3 main criteria: (1) Financial capacity shown in the latest year's financial statements; (2) Media credibility is assessed by Media Coding method - encoding articles about the company on influential media channels; (3) Survey of stakeholders was carried out in November, 2021. This result has confirmed the financial capacity, media credibility, and the trust of stakeholders and the social community for Traphaco JSC in 2021, a year full of changes and challenges.

The impressive numbers of revenue and profit growth that Traphaco has achieved in a really harsh business environment. For Traphaco, double-digit growth is the good news for a sustainable development strategy pursued many years ago. The complicated situation of the COVID-19 epidemic has shown that Traphaco's vision is right when bravely deploying Enterprise Digital Transformation early.

In the period of 2015 to 2017, with the strength of being the No. 1 oriental pharmaceutical company, Traphaco put all its efforts to build a 4.0 smart modern pharmaceutical factory. In the context of social distancing, the efficiency of the 4.0 technology factory is clearly promoted, when the stages are fully automated and closed; The best quality and output are guaranteed. Having enough goods for business purposes and timely supplying them for the purpose of supporting disease prevention.

Because the factory does not use many workers, the factory is not under great pressure on personnel and can perform "3 on the spot" proactively, safely and long-term. In particular, thanks to these characteristics, Traphaco can focus more on epidemic prevention products - a product group whose demand has increased many times.

In addition to increasing safe, self-produced goods, Traphaco also has a solution to "resolve" the risk of drug supply chain disruption in the context of difficult transportation and travel during the pandemic, through Traphaco's distribution chain with scale 28 branches, manage more than 27,000 drugstores nationwide.

The ability to adapt to the changing business environment is also evident in the fact that the business sector quickly changed its approach to customers, instead of directly visiting customers, switching to selling by phone, zalo... Programs to support pharmacies are built with a focus on epidemics, stabilizing selling prices, deploying many promotions and gifting points; Marketing tools are designed to suit the online sales scenario, helping the pharmacist to be proactive in his work.

With the clear business goal and strategy, it is "Maintaining and maintaining the No. 1 position in traditional medicine - focusing on investment and development in addition to traditional medicine". In 2021, Traphaco implemented a corporate restructuring project, through which the restructuring was carried out based on functional arrays according to the Traphaco value chain. Restructuring activities are inevitable, in line with the new situation, change for development, better for the Company and for Traphaco's employees. With the Decentralization Matrix, the responsibilities and tasks are clearly and transparently assigned, which is an opportunity for each position to demonstrate its capacity and promote its strengths.

In addition, in the 2021-2025 term, the goal is to increase total revenue at a compound rate of 13.3%, a compound profit before tax of 15%, and enhance technology transfer with Korean partner Daewoong with about 70 products, develop a breakthrough sale of new products. On November 26^th, 2021, the first batch of technology transfer product phase 1 - Ursodeoxycholic Acid 300mg (UDCA) was shipped to branches nationwide to be ready for sales. This is Traphaco's determination to not only maintain its leading position in herbal products, but also strongly develop non-traditional products in line with current market trends.